We get a mention...
"With all the buzz associated with Mannkind (MNKD) lately surrounding its Phase III Diabetes inhaler Afrezza, Biodel seems poised to take advantage of it as both companies are seeking to offer treatments in the same segment."
http://seekingalpha.com/article/1581942-biopharma-catalyst-trade-pick-of-the-week-biodel?source=google_news